Group 1 - The core transaction involves MicroPort Cardio Flow CRM Limited acquiring CRM Cayman through a merger agreement, with CRM Cayman becoming a wholly-owned subsidiary of MicroPort Cardio Flow upon completion [1][2] - The merger will involve the issuance of new shares at a price of HKD 1.35 per share to CRM Cayman shareholders, with a pre-transaction equity value of CRM Cayman estimated at USD 680 million [1][2] - The merger is strategically aligned with MicroPort Cardio Flow's business development, aiming to establish a global cardiac product platform and enhance its product offerings and capabilities in structural heart disease and arrhythmia management [2] Group 2 - CRM Cayman and its subsidiaries focus on arrhythmia management solutions, providing devices to monitor heart conditions and deliver treatments [2] - MicroPort Cardio Flow specializes in innovative transcatheter solutions for structural heart disease, with products including valve products and left atrial appendage occluders [2] - The merger is expected to create complementary synergies that will diversify and expand MicroPort Cardio Flow's existing business, particularly in research and development, manufacturing, distribution channels, and market expansion [2]

微创心通医疗科技有限公司是一家主要从事为医生和患者提供治疗结构性心脏病的全医疗方案的医疗器 械公司。该公司的主营业务是从事结构性心脏病领域的经导管及手术解决方案的研发和商业化。该公司 的产品管线包括经导管主动脉瓣植入术（TAVI）系列产品、AnchorMan左心耳封堵器（LAAC）产品、 经导管二尖瓣（TMV）产品、经导管三尖瓣（TTV）产品和手术配套产品。该公司在国内和国外市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，9月18日南向资金减持7.7万股心通医疗-B（02160.HK）。近5个交易日中，获南向资金 减持的有5天，累计净减持21.5万股。近20个交易日中，获南向资金减持的有20天，累计净减持287.6万 股。截至目前，南向资金持有心通医疗-B（02160.HK）1.12亿股，占公司已发行普通股的4.63%。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-09-18 | 1.12亿 | -7.70万 ...